CAR-T (Chimeric Antigen Receptor T-cell Therapy) is one of the most transformative breakthroughs in cancer treatment and the world's first gene-engineered cell therapy to achieve large-scale commercial success. At Chivanta, we examine CAR-T through a Biopharma × Business lens, exploring its science, manufacturing, commercialization, and next-generation innovations to understand what truly determines its long-term impact on patients and the industry.
CAR-T has transformed cancer treatment, but its One Patient, One Batch model limits scalability. Can allogeneic CAR-T overcome manufacturing scalability bottlenecks and redefine the future of cell therapy?
Manufacturing makes CAR-T possible. Hospitals make CAR-T scalable. CAR-T's biggest commercialization challenge isn't manufacturing alone. Hospital capacity—from patient selection and leukapheresis to CRS management and reimbursement—may be the real bottleneck limiting market expansion.
CAR-T therapy redefined what a drug could be. By engineering immune cells into living medicines, CAR-T opened a new era of cell therapy. Here explains how CAR-T works, designs and drives innovation, understanding the science and its greatest challenges.
CAR-T therapy has delivered remarkable clinical outcomes, yet scaling manufacturing remains one of the industry's greatest challenges. Learn why CAR-T isn't simply selling engineered cells—it's selling an entire vein-to-vein supply chain
CAR-T therapy transformed cancer treatment, but scientific breakthroughs alone don't guarantee commercial success. Discover why manufacturing, supply chains, hospital capacity, and reimbursement became the real bottlenecks behind CAR-T commercialization.
